BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BASF Pharmaceutical Solutions Presented at CPhI Worldwide in Frankfurt, Germany


9/26/2013 8:53:11 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

September 26, 2013 -- BASF representatives will be participating at CPhI Worldwide, the world’s largest pharmaceutical trade fair scheduled to take place in Frankfurt, Germany (hall 3.1, booth 31E19) from October 22 to 24, 2013. Under the umbrella of the corporate strategy “We create chemistry for a sustainable future”, BASF will reach out to customers and partners to discuss its intelligent end-to-end solutions and high-quality products such as active pharmaceutical ingredients (APIs), excipients, catalysts, reagents and inorganic specialties.

Omega-3 solutions for all requirements

By acquiring Pronova BioPharma, BASF has achieved a leading position in the global market for omega-3 fatty acids. This transaction complements the acquisition of Equateq, now BASF Pharma (Callanish), in May 2012 and expands BASF’s omega-3 portfolio. BASF’s offering now covers the full range of medium- to highly concentrated omega-3 fatty acids for use in nutrition, dietary supplements and pharmaceuticals.

BASF’s highly concentrated and extremely pure omega-3 fatty acids are used as APIs to treat cardiovascular diseases such as post-myocardial infarction and hyperlipidemia/hypertriglyceridemia; they are also used in nutritional applications, including dietary supplements.

Generic APIs to rely on

Omega-3 fatty acids are a recent major enhancement to BASF’s diverse API portfolio that has gained the trust of the pharmaceutical industry over many decades. BASF is a worldwide leading supplier of ibuprofen, caffeine, pseudoephedrine, theophylline and phenylephrine among many other generic active pharmaceutical ingredients. Exceptional bioavailability through innovative excipients

The challenge for pharmaceutical companies to enhance the solubility of active ingredients can only be tackled with the right solubilizers and process technologies. BASF is devoted to providing solutions for such solubilization challenges to support customers’ success, as proven for instance by the high-throughput screening robot Solu-HTS that speeds up the selection of the best solubilizer or combination for poorly soluble APIs.

BASF’s portfolio includes exceptional solubilizing agents such as the award-winning Soluplus® and the Kolliphor® and Kollidon® ranges. These products can be used in standard production processes as well as with innovative process technologies such as hot-melt extrusion (HME) for optimal results.

Skin delivery excellence

When it comes to topical formulations, every single ingredient counts; pharmaceutical quality is ideally rounded off with the right sensory experience. BASF is committed to best-in-class quality across the topical ingredients spectrum – whether emulsifiers, gel formers, consistency factors, solvents, actives or emollients. Customers are guaranteed the highest purity and reliability for their formulations.

Custom synthesis services to satisfy unique manufacturing requirements

BASF is a leading provider of custom APIs and intermediates for the pharmaceutical industry. Partnering with BASF gives customers the opportunity to establish long-term security of supply by relying on BASF’s proven track record in the pharmaceutical industry. Customers benefit from BASF’s manufacturing expertise and flexibility and gain access to its global research and development network, where value-added technologies are constantly emerging. Through its value proposition, BASF Custom Synthesis offers innovative solutions that help to simplify production processes and optimize costs.

High quality solvents and reagents to meet customers’ needs

BASF develops tailor-made products such as the recently launched Tetrakis (dimethylamino) diboron DMA4B2, thus meeting the very specific needs for the production of the API. The new boronation reagent for Suzuki coupling reactions offers full flexibility and works with a broad range of different solvents and catalysts. Moreover, it enables borylations to be carried out at higher concentrations and even in solvent-free reactions.

With its N-Methylpyrrolidone Life Science (NMP Life Science) BASF also offers another high quality product that provides an innovative solution for the pharmaceutical industry. Specially designed for use in pharmaceutical peptide synthesis and similar applications where high solvent purity is an advantage, NMP Life Science improves the process efficiency. Due to its low amine content of below 1 part per million (ppm) and low water content of below 0.03 percent, the yield in solid-phase peptide synthesis can be increased by up to 15 percent compared to standard grade NMP.

Environmentally-friendly catalysts

BASF Catalysts will be starting a production line for precious metal-based fine chemical catalysts at the company’s manufacturing site in Mangalore, India in October 2013. This marks BASF’s first manufacturing operation for chemical catalysts in Asia Pacific. With this new manufacturing line, BASF enhances its proximity to customers in the Asia Pacific region and expands its offerings to meet the needs of local pharmaceutical and fine chemical producers.

Among the technologies used in Mangalore for the production of precious-metal based catalysts will also be BASF's innovative NanoSelectTM platform technology. The NanoSelectTM technology already resulted in the development of the lead-free palladium (Pd) catalysts as a replacement for Lindlar catalysts. More recently highly efficient platinum-based catalysts were also developed which show, for example, high nitro group hydrogenation activity with lower platinum requirements. In addition, BASF's NanoSelect platform technology has enabled the production of modified platinum catalysts with good selectivity in halo nitro aromatic hydrogenation reactions.

Precious metal services

BASF Catalysts is also a worldwide leader in the field of platinum group metal management, and offers industrial customers a “full loop” of metal management services. From raw metal supply and scrap reclamation to financial risk management, BASF Catalysts professionals provide confidential, value enhancing solutions to our industrial clients seeking to optimize their precious metal portfolios.

More information is available at www.pharma.basf.com

Visit us at CPhI Worldwide

October 22-24, 2013

Hall 3.1, booth 31E19

Messe Frankfurt, Germany

About BASF

BASF is the world’s leading chemical company: The Chemical Company. Its portfolio ranges from chemicals, plastics, performance products and crop protection products to oil and gas. We combine economic success with environmental protection and social responsibility. Through science and innovation, we enable our customers in nearly every industry to meet the current and future needs of society. Our products and solutions contribute to conserving resources, ensuring nutrition and improving quality of life. We have summed up this contribution in our corporate purpose: We create chemistry for a sustainable future. BASF had sales of €72.1 billion in 2012 and more than 110,000 employees as of the end of the year. BASF shares are traded on the stock exchanges in Frankfurt (BAS), London (BFA) and Zurich (AN). Further information on BASF is available on the Internet: www.basf.com.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

BASF
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES